The purpose of this study was to retrospectively analyze the clinical feature, gene level and survival status of 79 patients with newly diagnosed CML-CP and assessed the relationship between the halving time threshold and BCR-ABL1IS at 3 months with molecule response, overall survival (OS), progression-free survival (PFS) and event-free survival (EFS). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.